Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8+ T cells

Oncology Reports

Volumn 35, Issue 2, 2016, Pages 699-708

  Leng, Changsen ^a   Li, Yin ^a   Qin, Jianjun ^a   Ma, Jun ^a   Liu, Xianben ^a   Cui, Yingying ^a   Sun, Haibo ^a   Wang, Zongfei ^a   Hua, Xionghuai ^a   Yu, Yongkui ^a   Li, Haomiao ^a   Zhang, Jun ^a   Zheng, Yan ^a   Wang, Wei ^a   Zhu, Junwei ^a   Wang, Qiuming ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

Esophageal squamous cell carcinoma; Immunotherapy; Programmed death 1; Programmed death ligands

Indexed keywords

GAMMA INTERFERON; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; CD274 PROTEIN, HUMAN; PDCD1LG2 PROTEIN, HUMAN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER TISSUE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNODEFICIENCY; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; EC109 CELL LINE; ESOPHAGEAL CANCER CELL LINE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENETIC TRANSFECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; BIOSYNTHESIS; CELL SEPARATION; ESOPHAGUS TUMOR; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TUMOR ESCAPE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD274; CARCINOMA, SQUAMOUS CELL; CD8-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; COCULTURE TECHNIQUES; ESOPHAGEAL NEOPLASMS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; PROGNOSIS; PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN; REAL-TIME POLYMERASE CHAIN REACTION; TRANSFECTION; TUMOR ESCAPE;

EID: 84954305178     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4435     Document Type: Article

References (52)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Cohen DJ and Ajani J: An expert opinion on esophageal cancer therapy. Expert Opin Pharmacother 12: 225-239, 2011.
3. Lagergren J and Lagergren P: Oesophageal cancer. BMJ 341: c6280, 2010.
4. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, et al; MAGIC Trial Participants: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355: 11-20, 2006.
5. Siewert JR, Lordick F, Ott K, Stein HJ, Weber WA, Becker K, Peschel C, Fink U and Schwaiger M: Induction chemotherapy in Barrett cancer: Influence on surgical risk and outcome. Ann Surg 246: 624-628, discussion 628-631, 2007.
6. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J and Simes J; Australasian Gastro Intestinal Trials Group: Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: A meta analysis. Lancet Oncol 8: 226-234, 2007.
7. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al: Tumorassociated B7H1 promotes Tcell apoptosis: A potential mechanism of immune evasion. Nat Med 8: 793-800, 2002.
8. Dong H and Chen L: B7H1 pathway and its role in the evasion of tumor immunity. J Mol Med (Berl) 81: 281-287, 2003.
9. Flies DB and Chen L: The new B7s: Playing a pivotal role in tumor immunity. J Immunother 30: 251-260, 2007.
10. Sharpe AH and Freeman GJ: The B7CD28 superfamily. Nat Rev Immunol 2: 116-126, 2002.
11. Ishida Y, Agata Y, Shibahara K and Honjo T: Induced expression of PD1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11: 3887-3895, 1992.
12. Nishimura H and Honjo T: PD1: An inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol 22: 265-268, 2001.
13. Dong H, Zhu G, Tamada K and Chen L: B7H1, a third member of the B7 family, costimulates Tcell proliferation and interleukin10 secretion. Nat Med 5: 1365-1369, 1999.
14. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, et al: Engagement of the PD1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192: 1027-1034, 2000.
15. Tseng SY, Otsuji M, Gorski K, Huang X, Slansky JE, Pai SI, Shalabi A, Shin T, Pardoll DM and Tsuchiya H: B7DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 193: 839-846, 2001.
16. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, et al: PDL2 is a second ligand for PD1 and inhibits T cell activation. Nat Immunol 2: 261-268, 2001.
17. Mahoney KM, Freeman GJ and McDermott DF: The next immune checkpoint inhibitors: PD1/PDL1 blockade in melanoma. Clin Ther 37: 764-782, 2015.
18. Massari F, Santoni M, Ciccarese C, Santini D, Alfieri S, Martignoni G, Brunelli M, Piva F, Berardi R, Montironi R, et al: PD1 blockade therapy in renal cell carcinoma: Current studies and future promises. Cancer Treat Rev 41: 114-121, 2015.
19. Suzuki H, Owada Y, Watanabe Y, Inoue T, Fukuharav M, Yamaura T, Mutoh S, Okabe N, Yaginuma H, Hasegawa T, et al: Recent advances in immunotherapy for non small cell lung cancer. Hum Vaccin Immunother 10: 352-357, 2014.
20. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al: Safety, activity, and immune correlates of anti PD1 antibody in cancer. N Engl J Med 366: 2443-2454, 2012.
21. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al: Safety and activity of anti PD L1 antibody in patients with advanced cancer. N Engl J Med 366: 2455-2465, 2012.
22. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H, et al: Tumor B7H1 is associated with poor prognosis in renal cell carcinoma patients with long term follow up. Cancer Res 66: 3381-3385, 2006.
23. Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, Mizuno T, Yoriki R, Kashizuka H, Yane K, et al: Clinical significance of programmed death1 ligand1 and programmed death1 ligand2 expression in human esophageal cancer. Clin Cancer Res 11: 2947-2953, 2005.
24. Cordon Cardo C, Fuks Z, Drobnjak M, Moreno C, Eisenbach L and Feldman M: Expression of HLAA,B,C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res 51: 6372-6380, 1991.
25. Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mulé JJ, Rosenberg SA and Bennink JR: Identification of human cancers deficient in antigen processing. J Exp Med 177: 265-272, 1993.
26. Ebrahimi B, Tucker SL, Li D, Abbruzzese JL and Kurzrock R: Cytokines in pancreatic carcinoma: Correlation with phenotypic characteristics and prognosis. Cancer 101: 2727-2736, 2004.
27. Pardoll D: Does the immune system see tumors as foreign or self? Annu Rev Immunol 21: 807-839, 2003.
28. Liu X, Gao JX, Wen J, Yin L, Li O, Zuo T, Gajewski TF, Fu YX, Zheng P and Liu Y: B7DC/PDL2 promotes tumor immunity by a PD1independent mechanism. J Exp Med 197: 1721-1730, 2003.
29. Okazaki T, Maeda A, Nishimura H, Kurosaki T and Honjo T: PD1 immunoreceptor inhibits B cell receptor mediated signaling by recruiting src homology 2 domain containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci USA 98: 13866-13871, 2001.
30. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, Sengupta S, Chen L, et al: Costimulatory B7H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA 101: 17174-17179, 2004.
31. Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K and Ueda S: Overexpression of B7H1 (PDL1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother 56: 1173-1182, 2007.
32. Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, Nakamura S, Enomoto K, Yagita H, Azuma M, et al: Clinical significance and therapeutic potential of the programmed death1 ligand/programmed death1 pathway in human pancreatic cancer. Clin Cancer Res 13: 2151-2157, 2007.
33. Loos M, Giese NA, Kleeff J, Giese T, Gaida MM, Bergmann F, Laschinger M, W Büchler M and Friess H: Clinical significance and regulation of the costimulatory molecule B7H1 in pancreatic cancer. Cancer Lett 268: 98-109, 2008.
34. Wu C, Zhu Y, Jiang J, Zhao J, Zhang XG and Xu N: Immunohistochemical localization of programmed death1 ligand1 (PDL1) in gastric carcinoma and its clinical significance. Acta Histochem 108: 19-24, 2006.
35. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, et al: Programmed cell death 1 ligand 1 and tumorinfiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 104: 3360-3365, 2007.
36. Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, Nakajima Y, Zhou J, Li BZ, Shi YH, Xiao YS, et al: Overexpression of PDL1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 15: 971-979, 2009.
37. Rosenberg SA: The immunotherapy of solid cancers based on cloning the genes encoding tumorrejection antigens. Annu Rev Med 47: 481-491, 1996.
38. Cho Y, Miyamoto M, Kato K, Fukunaga A, Shichinohe T, Kawarada Y, Hida Y, Oshikiri T, Kurokawa T, Suzuoki M, et al: CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res 63: 1555-1559, 2003.
39. Schumacher K, Haensch W, Röefzaad C and Schlag PM: Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res 61: 3932-3936, 2001.
40. Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E and Kosma VM: Prognostic value of tumourinfiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 182: 318-324, 1997.
41. Schroder K, Hertzog PJ, Ravasi T and Hume DA: Interferon gamma: An overview of signals, mechanisms and functions. J Leukoc Biol 75: 163-189, 2004.
42. Chemnitz JM, Parry RV, Nichols KE, June CH and Riley JL: SHP1 and SHP2 associate with immunoreceptor tyrosine based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 173: 945-954, 2004.
43. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, Linsley PS, Thompson CB and Riley JL: CTLA4 and PD1 receptors inhibit Tcell activation by distinct mechanisms. Mol Cell Biol 25: 9543-9553, 2005.
44. Nurieva R, Thomas S, Nguyen T, Martin Orozco N, Wang Y, Kaja MK, Yu XZ and Dong C: T cell tolerance or function is determined by combinatorial costimulatory signals. EMBO J 25: 2623-2633, 2006.
45. Riley JL: PD1 signaling in primary T cells. Immunol Rev 229: 114-125, 2009.
46. Rozali EN, Hato SV, Robinson BW, Lake RA and Lesterhuis J: Programmed death ligand 2 in cancer induced immune suppression. Clin Dev Immunol 2012: 656340, 2012.
47. Matsumoto K, Inoue H, Nakano T, Tsuda M, Yoshiura Y, Fukuyama S, Tsushima F, Hoshino T, Aizawa H, Akiba H, et al: B7DC regulates asthmatic response by an IFN gamma dependent mechanism. J Immunol 172: 2530-2541, 2004.
48. Ishiwata K, Watanabe N, Guo M, Tomihara K, Brumlik MJ, Yagita H, Pardoll D, Chen L and Shin T: Costimulator B7DC attenuates strong Th2 responses induced by Nippostrongylus brasiliensis. J Immunol 184: 2086-2094, 2010.
49. Wang S, Bajorath J, Flies DB, Dong H, Honjo T and Chen L: Molecular modeling and functional mapping of B7H1 and B7DC uncouple costimulatory function from PD1 interaction. J Exp Med 197: 1083-1091, 2003.
50. Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell 144: 646-674, 2011.
51. Yang W, Chen PW, Li H, Alizadeh H and Niederkorn JY: PDL1: PD1 interaction contributes to the functional suppression of Tcell responses to human uveal melanoma cells in vitro. Invest Ophthalmol Vis Sci 49: 2518-2525, 2008.
52. Topalian SL, Drake CG and Pardoll DM: Targeting the PD1/B7H1(PDL1) pathway to activate anti tumor immunity. Curr Opin Immunol 24: 207-212, 2012.